Company news

Jasper Therapeutics, Inc. news in 2024

Jasper Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

December 1, 2024

Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 6, 2024

Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

October 23, 2024

Jasper Therapeutics Announces Further Expansion of Clinical Program in Chronic Spontaneous Urticaria

October 22, 2024

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

October 13, 2024

Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma

September 9, 2024

Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

August 12, 2024

Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors

June 18, 2024

Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress

June 13, 2024

Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024

May 29, 2024

Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments

May 13, 2024

Jasper Therapeutics Announces Briquilimab Development Program in Asthma

May 12, 2024

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria

March 18, 2024

Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments

March 3, 2024

Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock

February 5, 2024

Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

February 4, 2024

Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 1, 2024

Jasper Therapeutics, Inc. Announces Reverse Stock Split

January 1, 2024

Decks in 2024